CoFlo Medical

Annular-flow drug-delivery devices for rapid, low-force injection of high-viscosity biologics.

Website: https://coflo-medical.com/

Cover Block

Open sources

Field Value
Name CoFlo Medical
Tagline Annular-flow drug-delivery devices for rapid, low-force injection of high-viscosity biologics.
Headquarters San Francisco, US [Dealroom, November 2026]
Founded 2022 [Dealroom, November 2026]
Stage Seed [Dealroom, November 2026]
Business model Hardware + Software
Industry Healthtech
Technology type Biotech / Life Sciences
Geography North America
Growth profile Venture Scale
Founding team Academic Spinout [MIT Sloan, May 2025]
Funding label Seed
Total disclosed ~$6,000,000 [Dealroom, November 2026]

Links

Open sources

What an Investor Needs First

PUBLIC CoFlo Medical is building annular-flow drug-delivery devices for highly viscous biologics, and it merits investor attention now because public reporting ties the company to a fresh $6 million seed round and an early set of pharmaceutical development relationships around a clinically relevant delivery bottleneck [Dealroom, November 2026] [MIT Sloan, May 2025]. The company emerged from MIT research and gained early visibility after winning the MIT $100K competition in 2025, with reporting and founder-linked profiles connecting the founding story to work by Simon Rufer, Vishnu Jayaprakash, Kripa K. Varanasi, and Geoffrey Vaartstra around a device intended to make difficult-to-inject biologics administrable through small needles [MIT Sloan, May 2025] [MIT School of Engineering, June 2025] [LinkedIn, retrieved 2026].

The product case rests on a specific technical claim rather than a broad platform narrative: CoFlo says its annular-flow approach surrounds a viscous drug with a lower-viscosity fluid, which the company and MIT coverage describe as enabling substantially faster delivery and lower injection force for formulations above 1,000 cP [CoFlo Medical, retrieved 2026] [MIT School of Engineering, June 2025]. That is commercially interesting because the company is positioning the device as a route to shift some therapies from hours-long intravenous infusions toward faster subcutaneous injections in clinics or potentially at home, although those use-case benefits remain largely company-stated at this stage [MIT Sloan, May 2025] [SignalBase, November 2026].

The team appears well matched to the underlying fluid-dynamics problem. Public materials identify Varanasi as an MIT mechanical engineering professor whose lab work underlies the technology, while MIT and LinkedIn-sourced reporting ties Rufer and Jayaprakash to the company as operating co-founders and public-facing commercial builders [Varanasi Research Group, retrieved 2026] [MIT School of Engineering, June 2025] [LinkedIn, retrieved 2026].

On capitalization, the cleanest disclosed financing signal is the November 2026 seed round, reported at $6 million and led by J2 Ventures, while Tracxn also lists a separate $500,000 seed entry dated November 2025 that is not clearly reconciled in public reporting [Dealroom, November 2026] [Tracxn, retrieved 2026]. The business model is best understood as hardware plus software sold into pharmaceutical and biopharmaceutical development workflows, with value creation likely tied to enabling high-concentration combination products rather than competing as a general-purpose injection device vendor [CoFlo Medical, retrieved 2026] [MIT Sloan, May 2025].

Over the next 12 to 18 months, the central watchpoints are straightforward: whether company-reported pharma engagements convert into named partnerships, regulated development milestones, or repeatable device programs, and whether the current performance claims gain validation beyond company materials and MIT competition coverage [MIT Sloan, May 2025] [DevCuration, November 2026] [MBC BioLabs, retrieved 2026]. The company has a credible technical wedge and early external interest, but the public record is still thin on customer identity, clinical evidence, and commercial proof, so diligence should stay anchored to validation depth rather than headline promise [Dealroom, November 2026] [CoFlo Medical, retrieved 2026].

Partially corroborated -- Relies on a mix of independent reporting from MIT Sloan, MIT School of Engineering, and Dealroom, with several material product and traction claims still resting on company materials or single-source reports.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Disclosed funding of about $6.0 million

Inside the Company

Open sources CoFlo Medical is a San Francisco-based healthtech startup developing annular-flow drug-delivery devices for highly concentrated, high-viscosity biologics [CoFlo Medical, retrieved 2026]. The company was founded in 2022 and presents itself as an MIT spinout built around fluid-dynamics research intended to make difficult-to-inject medicines deliverable through small needles [CoFlo Medical, retrieved 2026].

The public record here is still thin, which is typical at this stage. The clearest chronology supported by company and company-profile materials is: founding in 2022, early public visibility through its website and MIT-linked profile, then a disclosed $6 million seed round in November 2026 led by J2 Ventures [CoFlo Medical, retrieved 2026] [Dealroom, November 2026]. A separate Tracxn entry also lists a $500,000 seed financing dated November 5, 2025, but the available source set does not independently clarify whether that entry reflects a distinct round, an extension, or an earlier close within the same seed financing history [Tracxn].

The founding bench appears to combine commercialization and academic lineage, with public materials naming Simon Rufer, Vishnu Jayaprakash, Kripa K. Varanasi, and Geoffrey Vaartstra among the founding team tied to the MIT-origin technology [CoFlo Medical, retrieved 2026] [Varanasi Research Group, retrieved 2026]. No state filing or legal-entity detail was included in the supplied source set, so the overview is best read as a company-profile snapshot rather than a full corporate record.

Partially corroborated -- Confirmed in part by the company website and Dealroom, with some chronology supported by a single company-profile source.

Under the Hood

MIXED

The technical claim worth isolating is narrow but consequential: CoFlo Medical is building annular-flow drug-delivery devices intended to make highly viscous biologics injectable through small needles, rather than forcing a shift to longer infusion-based administration [CoFlo Medical, retrieved 2026] [MIT Sloan, May 2025] [MIT School of Engineering, June 2025]. Public descriptions are consistent on the mechanism. The device surrounds a high-viscosity drug with a lower-viscosity fluid as both move through the needle, which the company and MIT coverage say reduces the force required to deliver concentrated formulations [MIT School of Engineering, June 2025] [CoFlo Medical, retrieved 2026].

The performance language, however, is not yet fully harmonized across sources, so the safer read is directional rather than absolute. CoFlo’s website says its injectors can handle biologics beyond 1,000 cP with up to 100x lower injection force [CoFlo Medical, retrieved 2026]. MIT School of Engineering reported that the device can deliver biologic drugs more than 10 times faster than existing methods, while MIT graduate-education material described laboratory demonstrations of injections up to 200 times faster [MIT School of Engineering, June 2025] [Office of Graduate Education, retrieved 2026]. Those claims point to a real technical wedge, but they remain a mix of company statements and institutionally reported lab performance rather than disclosed clinical or commercial outcome data [MIT Sloan, May 2025] [Dealroom, November 2026].

The product posture appears closer to a platform component for pharma programs than a direct-to-provider device sale. MIT Sloan reported in May 2025 that the company was working with three pharmaceutical companies on six drugs, which suggests the immediate buyer is likely a drug developer trying to preserve subcutaneous administration for high-concentration biologics rather than a hospital procurement team [MIT Sloan, May 2025]. On operating maturity, public job postings point to hands-on device engineering work tied to scaling production and developing an FDA-ready device, which supports an interpretation that the stack is still device-heavy and translational, with any software layer secondary at this stage (inferred from job postings) [MBC BioLabs, retrieved 2026].

Partially corroborated -- Product mechanism is corroborated by the company website and MIT coverage, but key performance claims rely partly on company or institution-reported laboratory results.

Market Research

PUBLIC The market matters now because biologic drugs continue to move toward higher concentrations and more convenient administration formats, while delivery hardware remains a practical bottleneck for formulations that become difficult to inject at high viscosity [MIT Sloan, May 2025] [MIT School of Engineering, June 2025].

The public record does not provide a named third-party TAM, SAM, or SOM estimate specific to annular-flow injectors for high-viscosity biologics, so the cleaner approach is to frame CoFlo against the adjacent markets its sources actually describe. The company is targeting pharmaceutical and biopharmaceutical development programs where formulation viscosity can push treatment toward infusion rather than rapid injection, according to MIT coverage of the startup’s device concept [MIT Sloan, May 2025] [MIT School of Engineering, June 2025]. That places CoFlo in an enabling layer between drug formulation, drug-device combination products, and site-of-care economics, rather than in a broad generic medtech category.

Public demand signals are directional rather than fully quantified. MIT Sloan reported in May 2025 that CoFlo was already working with three pharmaceutical companies on six drugs, which suggests the pain point is showing up at the development-program level rather than only as a laboratory curiosity [MIT Sloan, May 2025]. By November 2026, Dealroom and related funding coverage tied the company’s seed round to the same core wedge, delivering highly viscous medicines through a small needle more quickly than infusion-based administration, although those articles did not publish contract values, development stage, or commercial conversion rates [Dealroom, November 2026] [SignalBase, November 2026].

The nearest adjacent markets are subcutaneous drug delivery devices, infusion therapy, and combination-product development for biologics. CoFlo’s own website and MIT reporting both anchor the problem around drugs beyond 1,000 cP viscosity and the prospect of moving some therapies from hours-long intravenous administration to seconds-long injection, including in clinics or at home, if the delivery challenge can be solved [CoFlo Medical] [MIT Sloan, May 2025] [MIT School of Engineering, June 2025]. As a market lens, that makes infusion an operational substitute and auto-injector or prefilled-syringe style delivery a target endpoint, even though the available sources do not establish which product form factors CoFlo will commercialize first.

Regulation and macro conditions cut both ways. On the positive side, any technology that helps sponsors convert infusion burden into injectable administration could fit long-running healthcare system incentives around lower-cost care settings, reduced chair time, and better patient convenience, as implied by MIT’s description of the shift from hospital infusions to rapid subcutaneous dosing [MIT Sloan, May 2025]. The constraint is that device performance alone does not create a market without validation inside regulated drug-device development pathways, and the surfaced job postings underscore that the company is still building toward an FDA-ready device rather than selling an already cleared platform [MBC BioLabs] [MIT School of Engineering, June 2025].

Market lens What the sources support Evidence quality
High-viscosity biologic delivery CoFlo is positioning around biologics above 1,000 cP viscosity and lower-force injection through small needles Company claim, partially contextualized by MIT coverage [CoFlo Medical] [MIT School of Engineering, June 2025]
Infusion-to-injection substitution Sources describe a goal of shifting some treatments from hours-long IV infusions to seconds-long injections Independent narrative support, but no quantified market size [MIT Sloan, May 2025] [SignalBase, November 2026]
Pharma development demand Reported work with three pharmaceutical companies on six drugs as of May 2025 Single named source, no customer names [MIT Sloan, May 2025]
Regulated combination products Job materials reference work toward an FDA-ready device and high-concentration combination products Mixed evidence from public job posting and MIT reporting [MBC BioLabs] [MIT School of Engineering, June 2025]

The practical read is that this is a real and intelligible market problem, but the public evidence is still better at describing the bottleneck than sizing the budget pool. Investors should treat CoFlo as selling into a narrow, high-value development constraint inside biologics rather than underwriting a broad medtech market figure that the current sources do not support.

Partially corroborated -- Section relies on MIT coverage, Dealroom and SignalBase funding reports, the company website, and one public job posting; market sizing remains indirect because no named third-party TAM study was provided.

Competition and Substitutes

MIXED CoFlo Medical appears less like a direct go-to-market contest against a named peer today, and more like a technology insertion play against the existing drug-delivery stack used by large pharmaceutical companies developing high-viscosity biologics [MIT Sloan, May 2025] [CoFlo Medical, retrieved 2026].

The practical competitive map is therefore segment-based rather than company-led. In the incumbent layer, the status quo is intravenous infusion for therapies that are difficult to push through a small needle, a workflow CoFlo says it can compress into rapid injection by reducing force requirements for biologics above 1,000 cP viscosity [CoFlo Medical, retrieved 2026] [MIT School of Engineering, June 2025]. In the adjacent substitute layer, the relevant alternatives are existing subcutaneous delivery approaches and combination-product development programs inside pharmaceutical companies, because CoFlo is selling into drug developers rather than marketing a branded therapy to patients or providers [MIT Sloan, May 2025]. No named independent startup competitors were confirmed in the source set, which itself is informative: the public record around CoFlo is still centered on technical feasibility and pharma collaboration, not on a clearly disclosed head-to-head field battle [Dealroom, November 2026] [DevCuration, November 2026].

Where CoFlo seems to have an edge today is in technical novelty tied to academic provenance, though the durability of that edge remains unproven in public. The company traces its approach to MIT-linked fluid-dynamics research, and co-founder Kripa K. Varanasi is identified by MIT as a professor of mechanical engineering whose research underlies the technology [Varanasi Research Group, retrieved 2026] [MIT School of Engineering, June 2025]. Public materials also point to early commercial access, with MIT Sloan reporting in May 2025 that the company was working with three pharmaceutical companies on six drugs, and later funding coverage repeating a company-reported claim of work with five of the 20 largest pharmaceutical companies [MIT Sloan, May 2025] [DevCuration, November 2026]. That combination, scientific pedigree plus early pharma design-in activity, can matter in drug delivery because switching costs rise once a device concept gets tied to formulation work. Even so, the evidence base is still thin: no named customers, approvals, or late-stage programs were publicly confirmed, so any edge on distribution or regulatory execution should be treated as perishable rather than locked in [MIT Sloan, May 2025] [SignalBase, November 2026].

The main exposure is not a confirmed startup rival with a larger balance sheet, but the breadth of the incumbent pharmaceutical and device ecosystem that already controls formulation, clinical development, and commercialization channels. CoFlo's own reported wedge depends on persuading drug developers that annular-flow delivery meaningfully outperforms established development paths for high-concentration biologics, and the public proof points are still mostly company or MIT-affiliated descriptions of speed and force reduction rather than third-party comparative studies [CoFlo Medical, retrieved 2026] [MIT School of Engineering, June 2025]. That leaves the company exposed to slower adoption if pharma partners decide that reformulation, standard injector architectures, or infusion-based administration remain good enough for priority assets. It also suggests a category boundary: CoFlo may influence combination-product design, but the current public record does not show that it owns the downstream provider channel, patient relationship, or a stand-alone therapeutics franchise [MIT Sloan, May 2025] [Dealroom, November 2026].

Over the next 18 months, the most plausible competitive outcome is still decided inside partner pipelines rather than in open-market share data. CoFlo is the likely winner if its existing pharmaceutical engagements convert into named development programs or device-selection milestones, because that would turn a promising platform claim into evidence of embedment inside real drug programs [MIT Sloan, May 2025] [DevCuration, November 2026]. The likely loser if adoption stalls is the infusion-first status quo for the subset of biologics that can be reformulated or delivered subcutaneously only if force constraints are solved, although that loss remains conditional because public sources do not yet document a commercial displacement event [MIT School of Engineering, June 2025] [CoFlo Medical, retrieved 2026]. The more conservative reading is that CoFlo has opened a credible flank in drug delivery, but the competitive field will stay opaque until counterparties, programs, or comparative validation become public.

Claim stands unchecked -- This section relies materially on company claims and MIT-affiliated coverage, with no named public competitors or independently verified head-to-head comparisons in the source set.

Opportunity

PUBLIC

The prize here is not a somewhat better injector, but a new delivery layer for biologics if CoFlo can make high-viscosity drugs practical as fast subcutaneous injections rather than hours-long infusions [MIT Sloan, May 2025] [MIT School of Engineering, June 2025].

The headline opportunity is straightforward: become the preferred device partner for pharmaceutical companies trying to push more concentrated biologics through small needles without unacceptable injection force. The public evidence is still early, but it is more than conceptual. MIT Sloan reported in May 2025 that CoFlo was already working with three pharmaceutical companies across six drugs, and MIT School of Engineering reported in June 2025 that the device could deliver biologic drugs more than 10 times faster than existing methods [MIT Sloan, May 2025] [MIT School of Engineering, June 2025]. Dealroom then reported a $6 million seed round led by J2 Ventures in November 2026, which matters less as validation of technical performance than as evidence that the company has moved beyond a lab-only project into financed commercialization work [Dealroom, November 2026].

The upside path is easiest to understand as a small set of commercialization scenarios rather than a single outcome. Each turns on the same underlying claim: if annular-flow delivery materially expands the set of biologics that can move from infusion to injection, the company can sell into a large and well-funded pharma workflow where device choice can shape both patient convenience and product economics [CoFlo Medical, retrieved 2026] [MIT Sloan, May 2025].

Scenario What happens Catalyst Why it's plausible
Formulation-enablement partner CoFlo becomes the specialist device company that pharma teams bring in when a high-concentration biologic is hard to inject through conventional formats. One or more current pharma programs move from evaluation into formal development or combination-product work [MIT Sloan, May 2025]. The company was reported to be working with three pharmaceutical companies on six drugs by May 2025, which suggests the wedge is already program-specific rather than purely promotional [MIT Sloan, May 2025].
Infusion-to-injection conversion platform CoFlo's device is used to help convert selected therapies from clinic-based infusions into rapid injections for clinics or home administration. A development partner shows that high-viscosity delivery can be completed in seconds through a small needle, consistent with the company's public product thesis [MIT School of Engineering, June 2025] [CoFlo Medical, retrieved 2026]. Both MIT reporting and the company's website describe the same core value proposition: lower-force delivery for very viscous biologics, potentially shifting some treatments out of long infusion workflows [MIT School of Engineering, June 2025] [CoFlo Medical, retrieved 2026].
Category licensing layer CoFlo licenses or co-develops its annular-flow architecture across multiple drug programs and device makers, becoming enabling infrastructure rather than a single-product vendor. A first major pharma or device-manufacturer relationship creates repeatable demand across a portfolio of formulations [MIT Sloan, May 2025]. Simon Rufer told MIT Sloan that interest extended beyond pharma to device manufacturers, hospitals, and institutions, which supports the idea that the technology could travel across several commercialization channels if initial results hold [MIT Sloan, May 2025].

What compounding would look like is also fairly legible. In the best case, each successful drug program does not just generate revenue, it de-risks the next one by proving the device can handle another difficult formulation class. That kind of referenceability matters in drug delivery, where adoption often spreads program by program rather than through broad consumer-style distribution. The early signal is modest but relevant: by May 2025 the company was reported to be working on six drugs with three pharmaceutical companies, implying multiple shots on goal from a small base [MIT Sloan, May 2025]. If those engagements deepen, CoFlo could accumulate formulation know-how, development relationships, and integration experience that make it harder to displace on later programs, especially if the device helps rescue molecules that are otherwise constrained by viscosity [CoFlo Medical, retrieved 2026] [MIT School of Engineering, June 2025].

The size of the win is hard to benchmark precisely from the public record because no credible market-size source was provided in the materials and no direct public comparable was confirmed in the source set. Even so, the economic logic is clear enough to frame the upside. If CoFlo becomes a recurring platform supplier to large pharma programs, with value tied to enabling administration routes that improve convenience and potentially lower care-delivery burden, the outcome could be strategic rather than incremental (scenario, not a forecast) [MIT Sloan, May 2025] [Dealroom, November 2026]. In practice, that would place the company on a path where worth is determined less by stand-alone device sales and more by how central its technology becomes to high-value biologic franchises. Public evidence is not yet strong enough to attach a defensible valuation range, but it is strong enough to say the company is pursuing a platform-sized problem rather than a narrow feature improvement [MIT School of Engineering, June 2025] [CoFlo Medical, retrieved 2026].

Partially corroborated -- Relies on MIT coverage and Dealroom for independent corroboration, with key performance and commercialization details still partly company-reported.

Sources

Open sources

  1. [Dealroom, November 2026] CoFlo Medical raises $6M Seed to rethink the injection needle | https://dealroom.co/news/174777-coflo-medical-raises-6m-seed-to-rethink-the-injection-needle/

  2. [MIT Sloan, May 2025] CoFlo Medical’s plan for faster, cheaper drug injection wins MIT $100K | https://mitsloan.mit.edu/ideas-made-to-matter/coflo-medicals-plan-faster-cheaper-drug-injection-wins-mit-100k

  3. [LinkedIn, retrieved 2026] Nikolaos Tsakiris - Graduate Researcher at MIT | Climate Tech & Ocean Carbon Capture | LinkedIn | https://www.linkedin.com/in/nikolaos-tsakiris/

  4. [MIT School of Engineering, June 2025] Drug injection device wins MIT $100K Competition | https://engineering.mit.edu/connect/news/drug-injection-device-wins-mit-100k-competition/

  5. [CoFlo Medical, retrieved 2026] CoFlo Medical: Inject the Uninjectable | https://coflo-medical.com/

  6. [SignalBase, November 2026] CoFlo Medical Raises $6.0M Seed Round for High-Viscosity Drug Delivery | https://www.trysignalbase.com/news/funding/coflo-medical-raises-6m-seed-round-for-high-viscosity-drug-delivery

  7. [Varanasi Research Group, retrieved 2026] People - Varanasi Research Group - MIT | https://varanasi.mit.edu/people/

  8. [MBC BioLabs, retrieved 2026] Senior / Principal Device Engineer - Drug Delivery | https://mbcbiolabs.com/job/coflo-medical-san-francisco-full-time-senior-principal-device-engineer-drug-delivery-2/

  9. [DevCuration, November 2026] CoFlo Medical Announces $6M Seed for Drug Delivery | https://devcuration.com/articles/coflo-medical-6m-seed-drug-delivery

Articles about CoFlo Medical

View on Startuply.vc